Onvansertib
- Generic Name
- Onvansertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F3N8O3
- CAS Number
- 1034616-18-6
- Unique Ingredient Identifier
- 67RM91WDHQ
- Background
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
- Associated Conditions
- -
- Associated Therapies
- -
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 68
- Registration Number
- NCT03829410
- Locations
- 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03414034
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03303339
- Locations
- 🇺🇸
Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.